ASX
LCT    Last updated
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Development to date

LCT commenced a Phase IIb study in March 2016. The study aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. The study is being led by Dr. Barry Snow at Auckland City Hospital. 


If the trial is successful we will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

 

Phase I/IIa

A Phase I/IIa clinical trial for NTCELL® for Parkinson’s disease was completed in June 2015.
 

The clinical trial was an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson’s disease for at least five years. 
 

The study, conducted in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant.

 

Preclinical data

In pre-clinical trials we induced a Parkinson's-like disorder in non-human primates and then implanted a single dose of NTCELL into the damaged dopaminergic region of their brain. The subjects implanted with NTCELL showed improvements in both motor and cognitive functions compared to the controls. The improvements were sustained for at least six months (the end of the study). Histological analysis showed an increase in the density of dopamine-producing nerve fibres in the NTCELL subjects compared to the controls. There was no evidence of inflammation or any other adverse event.

 

PRINT PAGE
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.